CSIMarket Company Name, Ticker, Suppliers, else..
 
Orchestra Biomed Holdings Inc   (NASDAQ: OBIO)
 
Price: $6.0400 $0.14 2.373%
Day's High: $6.130000114440918 Week Perf: 10.83 %
Day's Low: $ 5.93 30 Day Perf: 36.96 %
Volume (M): 228,281 52 Wk High: $ 6.25
Volume (M$): $ 0 52 Wk Avg: $4.15
Open: $6.00 52 Wk Low: $2.20



 Market Capitalization (Millions $) 385
 Shares Outstanding (Millions) 64
 Employees 86
 Revenues (TTM) (Millions $) 32
 Net Income (TTM) (Millions $) -59
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 1

Business Description


Orchestra Biomed Holdings Inc is a medical device company that focuses on the development and commercialization of innovative therapies for the treatment of cardiovascular diseases. The company is dedicated to developing advanced solutions for patients suffering from various cardiac conditions, including heart failure and heart attacks.

Orchestra Biomed Holdings Inc is known for its proprietary technology called the Virtue sirolimus-eluting balloon, which is designed to deliver targeted drug therapy to the diseased blood vessels. This technology aims to improve the effectiveness and safety of interventional cardiovascular procedures, providing better outcomes for patients.

The company's mission is to advance the field of cardiovascular medicine by developing groundbreaking therapies that address the unmet needs of patients. Through their research and development efforts, Orchestra Biomed Holdings Inc aims to revolutionize the treatment of cardiovascular diseases and ultimately improve the quality of life for patients worldwide.

Overall, Orchestra Biomed Holdings Inc is a medical device company that specializes in developing innovative therapies for cardiovascular diseases, with a focus on improving patient outcomes and advancing the field of cardiovascular medicine.


   Company Address: 150 Union Square Drive New Hope 18938 PA
   Company Phone Number: 862-5797   Stock Exchange / Ticker: NASDAQ OBIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAX   -4.63%    
BDX        3.81% 
BSX   -2.47%    
EW   -1.13%    
MDT        1.47% 
SYK        1.83% 
• View Complete Report
   



Announcement

Orchestra BioMed to Unveil Breakthrough Hypertensive Pacemaker Therapy Program at In-Person R&D Day in New York

Published Tue, Apr 30 2024 12:01 PM UTC

Orchestra BioMed Holdings, an innovative biomedical company, has announced that it will be hosting an exclusive in-person Research and Development (R&D) day on June 11, 2024, at the prestigious Lotte New York Palace Hotel. The event will provide a platform for Orchestra BioMed to showcase their pioneering AVIM Therapy Program, specifically designed for hypertensive pacemaker...
Clinical Study

Atrioventricular Interval Modulation (AVIM) Therapy Demonstrates Favorable Hemodynamic Effects in Hypertensive Pacemaker Patients

Published Wed, Mar 6 2024 1:37 PM UTC

Orchestra BioMed Holdings, Inc. recently conducted a clinical study to evaluate the efficacy of Atrioventricular Interval Modulation (AVIM) therapy, also known as BackBeat CNT, in pacemaker-indicated patients with uncontrolled hypertension. The study aimed to compare AVIM therapy with standard right ventricular (RV) pacing in terms of systolic blood pressure and overall card...
Clinical Study

Evaluating the Efficacy and Safety of Atrioventricular Interval Modulation Therapy for Hypertensive Pacemaker Patients: The BACKBEAT Pivotal Study

Published Mon, Jan 8 2024 12:30 PM UTC

- Hypertension remains a significant global health concern, affecting millions of individuals worldwide.- Conventional pharmacological therapies for hypertension may not always effectively control blood pressure in certain patient populations, including those with pacemakers.- Orchestra BioMed Holdings, Inc. has initiated the BACKBEAT pivotal study to evaluate the potential ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 12.05
Price to Sales (Expected) -
Price to Book 19.95
PEG (TTM) -

Financial Strength Current
Quick Ratio 8.16
Working Capital Ratio 8.26
Leverage Ratio (MRQ) 4.99
Total Debt to Equity 1.8
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.98 $
Revenues (TTM) 0.5 $
Cash Flow (TTM) 0.15 $
Cash 1.72 $
Book Value 0.3 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 371,814
Net Income per Employee (TTM) -685,570
Receivable Turnover Ratio (TTM) 453.56
Inventory Turnover Ratio (TTM) 0.52
Asset Turnover Ratio (TTM) 0.29

Profitability Ratios Current
Gross Margin (MRQ) 71.59 %
Operating Margin (MRQ) -25404.55 %
Net Margin (MRQ) -26994.32 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Orchestra Biomed Holdings Inc's Segments
Single Reportable Product revenue    225 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.